Tokyo Tape
Sign in
← M3

Quarterly report · Q1

2413.TEDINET S100OUDD
Period2022-04-01 → 2022-06-30
Filed2022-08-05
StandardIFRS
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 47
MetricValuePeriodScopeSource row
Revenue¥57.0bn2022-04-01 → 2022-06-30Cons.Revenue IFRS
Revenue¥208.2bn2021-04-01 → 2022-03-31Cons.Revenue IFRS (5-year summary)
Revenue¥46.4bn2021-04-01 → 2021-06-30Cons.Revenue IFRS
Operating income¥18.7bn2022-04-01 → 2022-06-30Cons.Operating profit loss IFRS
Operating income¥24.7bn2021-04-01 → 2021-06-30Cons.Operating profit loss IFRS
Profit before tax¥19.7bn2022-04-01 → 2022-06-30Cons.Profit loss before tax IFRS
Profit before tax¥96.2bn2021-04-01 → 2022-03-31Cons.Profit loss before tax IFRS (5-year summary)
Profit before tax¥24.8bn2021-04-01 → 2021-06-30Cons.Profit loss before tax IFRS
Net income (owners)¥12.1bn2022-04-01 → 2022-06-30Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥63.8bn2021-04-01 → 2022-03-31Cons.Profit loss attributable to owners of parent IFRS (5-year summary)
Net income (owners)¥15.8bn2021-04-01 → 2021-06-30Cons.Profit loss attributable to owners of parent IFRS
Net income¥13.5bn2022-04-01 → 2022-06-30Cons.Profit loss IFRS
Net income¥16.9bn2021-04-01 → 2021-06-30Cons.Profit loss IFRS
Total assets¥357.5bnat 2022-06-30Cons.Assets IFRS
Total assets¥346.0bnat 2022-03-31Cons.Assets IFRS
Total assets¥272.0bnat 2021-06-30Cons.Total assets IFRS (5-year summary)
Total liabilities¥82.4bnat 2022-06-30Cons.Liabilities IFRS
Total liabilities¥82.0bnat 2022-03-31Cons.Liabilities IFRS
Net assets / equity¥275.1bnat 2022-06-30Cons.Equity IFRS
Net assets / equity¥264.0bnat 2022-03-31Cons.Equity IFRS
Net assets / equity¥211.6bnat 2021-06-30Cons.Equity IFRS
Net assets / equity¥207.3bnat 2021-03-31dCons.Equity IFRS
Equity (owners)¥268.8bnat 2022-06-30Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥257.8bnat 2022-03-31Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥206.2bnat 2021-06-30Cons.Equity attributable to owners of parent IFRS (5-year summary)
Cash & equivalents¥88.8bnat 2022-06-30Cons.Cash and cash equivalents IFRS
Cash & equivalents¥104.3bnat 2022-03-31Cons.Cash and cash equivalents IFRS
Cash & equivalents¥79.9bnat 2021-06-30Cons.Cash and cash equivalents IFRS
Cash & equivalents¥89.1bnat 2021-03-31dCons.Cash and cash equivalents IFRS
Operating cash flow¥9.4bn2022-04-01 → 2022-06-30Cons.Net cash provided by used in operating activities IFRS
Operating cash flow¥52.1bn2021-04-01 → 2022-03-31Cons.Cash flows from used in operating activities IFRS (5-year summary)
Operating cash flow¥8.1bn2021-04-01 → 2021-06-30Cons.Net cash provided by used in operating activities IFRS
Investing cash flow−¥14.7bn2022-04-01 → 2022-06-30Cons.Net cash provided by used in investing activities IFRS
Investing cash flow−¥23.4bn2021-04-01 → 2022-03-31Cons.Cash flows from used in investing activities IFRS (5-year summary)
Investing cash flow−¥6.1bn2021-04-01 → 2021-06-30Cons.Net cash provided by used in investing activities IFRS
Financing cash flow−¥12.5bn2022-04-01 → 2022-06-30Cons.Net cash provided by used in financing activities IFRS
Financing cash flow−¥16.4bn2021-04-01 → 2022-03-31Cons.Cash flows from used in financing activities IFRS (5-year summary)
Financing cash flow−¥11.3bn2021-04-01 → 2021-06-30Cons.Net cash provided by used in financing activities IFRS
EPS (basic)¥17.862022-04-01 → 2022-06-30Cons.Basic earnings loss per share IFRS
EPS (basic)¥94.062021-04-01 → 2022-03-31Cons.Basic earnings loss per share IFRS (5-year summary)
EPS (basic)¥23.232021-04-01 → 2021-06-30Cons.Basic earnings loss per share IFRS
EPS (diluted)¥17.852022-04-01 → 2022-06-30Cons.Diluted earnings loss per share IFRS
EPS (diluted)¥93.982021-04-01 → 2022-03-31Cons.Diluted earnings loss per share IFRS (5-year summary)
EPS (diluted)¥23.212021-04-01 → 2021-06-30Cons.Diluted earnings loss per share IFRS
Equity ratio75.2%at 2022-06-30Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio74.5%at 2022-03-31Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio75.8%at 2021-06-30Cons.Ratio of owners equity to gross assets IFRS (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 53
SegmentItemPeriodValue
Reconciling Itemsreconcilingrevenue2022-04-01 → 2022-06-30−¥1.7bn
Reconciling Itemsreconcilingrevenue intersegment2022-04-01 → 2022-06-30−¥1.7bn
Reconciling Itemsreconcilingsegment profit2022-04-01 → 2022-06-30−¥471m
jpcrp040300-q1r_E05425-000Career Solutionreportable segmentrevenue2022-04-01 → 2022-06-30¥5.5bn
jpcrp040300-q1r_E05425-000Career Solutionreportable segmentrevenue external2022-04-01 → 2022-06-30¥5.2bn
jpcrp040300-q1r_E05425-000Career Solutionreportable segmentrevenue intersegment2022-04-01 → 2022-06-30¥267m
jpcrp040300-q1r_E05425-000Career Solutionreportable segmentsegment profit2022-04-01 → 2022-06-30¥2.8bn
jpcrp040300-q1r_E05425-000Evidence Solutionreportable segmentrevenue2022-04-01 → 2022-06-30¥7.2bn
jpcrp040300-q1r_E05425-000Evidence Solutionreportable segmentrevenue external2022-04-01 → 2022-06-30¥7.0bn
jpcrp040300-q1r_E05425-000Evidence Solutionreportable segmentrevenue intersegment2022-04-01 → 2022-06-30¥162m
jpcrp040300-q1r_E05425-000Evidence Solutionreportable segmentsegment profit2022-04-01 → 2022-06-30¥2.2bn
jpcrp040300-q1r_E05425-000Medical Platformreportable segmentrevenue2022-04-01 → 2022-06-30¥20.2bn
jpcrp040300-q1r_E05425-000Medical Platformreportable segmentrevenue external2022-04-01 → 2022-06-30¥19.3bn
jpcrp040300-q1r_E05425-000Medical Platformreportable segmentrevenue intersegment2022-04-01 → 2022-06-30¥951m
jpcrp040300-q1r_E05425-000Medical Platformreportable segmentsegment profit2022-04-01 → 2022-06-30¥8.8bn
jpcrp040300-q1r_E05425-000Overseasreportable segmentrevenue2022-04-01 → 2022-06-30¥14.9bn
jpcrp040300-q1r_E05425-000Overseasreportable segmentrevenue external2022-04-01 → 2022-06-30¥14.9bn
jpcrp040300-q1r_E05425-000Overseasreportable segmentrevenue intersegment2022-04-01 → 2022-06-30¥2m
jpcrp040300-q1r_E05425-000Overseasreportable segmentsegment profit2022-04-01 → 2022-06-30¥4.0bn
jpcrp040300-q1r_E05425-000Site Solutionreportable segmentrevenue2022-04-01 → 2022-06-30¥10.2bn
jpcrp040300-q1r_E05425-000Site Solutionreportable segmentrevenue external2022-04-01 → 2022-06-30¥9.9bn
jpcrp040300-q1r_E05425-000Site Solutionreportable segmentrevenue intersegment2022-04-01 → 2022-06-30¥304m
jpcrp040300-q1r_E05425-000Site Solutionreportable segmentsegment profit2022-04-01 → 2022-06-30¥1.4bn
—segment totalrevenue2022-04-01 → 2022-06-30¥58.0bn
—segment totalrevenue external2022-04-01 → 2022-06-30¥56.3bn
—segment totalrevenue intersegment2022-04-01 → 2022-06-30¥1.7bn
—segment totalsegment profit2022-04-01 → 2022-06-30¥19.3bn
Reconciling Itemsreconcilingrevenue2021-04-01 → 2021-06-30−¥947m
Reconciling Itemsreconcilingrevenue intersegment2021-04-01 → 2021-06-30−¥947m
Reconciling Itemsreconcilingsegment profit2021-04-01 → 2021-06-30−¥144m
jpcrp040300-q1r_E05425-000Career Solutionreportable segmentrevenue2021-04-01 → 2021-06-30¥4.9bn
jpcrp040300-q1r_E05425-000Career Solutionreportable segmentrevenue external2021-04-01 → 2021-06-30¥4.9bn
jpcrp040300-q1r_E05425-000Career Solutionreportable segmentrevenue intersegment2021-04-01 → 2021-06-30¥26m
jpcrp040300-q1r_E05425-000Career Solutionreportable segmentsegment profit2021-04-01 → 2021-06-30¥2.5bn
jpcrp040300-q1r_E05425-000Evidence Solutionreportable segmentrevenue2021-04-01 → 2021-06-30¥4.8bn
jpcrp040300-q1r_E05425-000Evidence Solutionreportable segmentrevenue external2021-04-01 → 2021-06-30¥4.6bn
jpcrp040300-q1r_E05425-000Evidence Solutionreportable segmentrevenue intersegment2021-04-01 → 2021-06-30¥195m
jpcrp040300-q1r_E05425-000Evidence Solutionreportable segmentsegment profit2021-04-01 → 2021-06-30¥858m
jpcrp040300-q1r_E05425-000Medical Platformreportable segmentrevenue2021-04-01 → 2021-06-30¥18.9bn
jpcrp040300-q1r_E05425-000Medical Platformreportable segmentrevenue external2021-04-01 → 2021-06-30¥18.2bn
jpcrp040300-q1r_E05425-000Medical Platformreportable segmentrevenue intersegment2021-04-01 → 2021-06-30¥690m
jpcrp040300-q1r_E05425-000Medical Platformreportable segmentsegment profit2021-04-01 → 2021-06-30¥8.2bn
jpcrp040300-q1r_E05425-000Overseasreportable segmentrevenue2021-04-01 → 2021-06-30¥12.7bn
jpcrp040300-q1r_E05425-000Overseasreportable segmentrevenue external2021-04-01 → 2021-06-30¥12.7bn
jpcrp040300-q1r_E05425-000Overseasreportable segmentrevenue intersegment2021-04-01 → 2021-06-30¥12m
jpcrp040300-q1r_E05425-000Overseasreportable segmentsegment profit2021-04-01 → 2021-06-30¥13.0bn
jpcrp040300-q1r_E05425-000Site Solutionreportable segmentrevenue2021-04-01 → 2021-06-30¥5.3bn
jpcrp040300-q1r_E05425-000Site Solutionreportable segmentrevenue external2021-04-01 → 2021-06-30¥5.3bn
jpcrp040300-q1r_E05425-000Site Solutionreportable segmentsegment profit2021-04-01 → 2021-06-30¥520m
—segment totalrevenue2021-04-01 → 2021-06-30¥46.6bn
—segment totalrevenue external2021-04-01 → 2021-06-30¥45.7bn
—segment totalrevenue intersegment2021-04-01 → 2021-06-30¥923m
—segment totalsegment profit2021-04-01 → 2021-06-30¥25.0bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 594
ItemContextValueUnit
Provisons for customer loyalty program cl IFRSPrior1YearInstant2739000000JPY
Provisons for customer loyalty program cl IFRSCurrentQuarterInstant2765000000JPY
Other financial liabilities cl IFRSPrior1YearInstant3812000000JPY
Other financial liabilities cl IFRSCurrentQuarterInstant3806000000JPY
Other current liabilities cl IFRSPrior1YearInstant10565000000JPY
Other current liabilities cl IFRSCurrentQuarterInstant10709000000JPY
Total current liabilities IFRSPrior1YearInstant57216000000JPY
Total current liabilities IFRSCurrentQuarterInstant53141000000JPY
Other financial liabilities ncl IFRSPrior1YearInstant6674000000JPY
Other financial liabilities ncl IFRSCurrentQuarterInstant8880000000JPY
Deferred tax liabilities IFRSPrior1YearInstant13479000000JPY
Deferred tax liabilities IFRSCurrentQuarterInstant15734000000JPY
Other non current liabilities ncl IFRSPrior1YearInstant4658000000JPY
Other non current liabilities ncl IFRSCurrentQuarterInstant4657000000JPY
Non current labilities IFRSPrior1YearInstant24811000000JPY
Non current labilities IFRSCurrentQuarterInstant29271000000JPY
Liabilities IFRSPrior1YearInstant82027000000JPY
Liabilities IFRSCurrentQuarterInstant82412000000JPY
Share capital IFRSPrior1YearInstant29129000000JPY
Share capital IFRSCurrentQuarterInstant29141000000JPY
Capital surplus IFRSPrior1YearInstant29704000000JPY
Capital surplus IFRSCurrentQuarterInstant29716000000JPY
Treasury shares IFRSPrior1YearInstant-36000000JPY
Treasury shares IFRSCurrentQuarterInstant-36000000JPY
Other components of equity IFRSPrior1YearInstant6131000000JPY
Other components of equity IFRSCurrentQuarterInstant15718000000JPY
Retained earnings IFRSPrior1YearInstant192912000000JPY
Retained earnings IFRSCurrentQuarterInstant194236000000JPY
Equity attributable to owners of parent IFRSPrior1YearInstant257840000000JPY
Equity attributable to owners of parent IFRSCurrentQuarterInstant268774000000JPY
Non controlling interests IFRSPrior1YearInstant6113000000JPY
Non controlling interests IFRSCurrentQuarterInstant6277000000JPY
Equity IFRSPrior1YearInstant263954000000JPY
Equity IFRSCurrentQuarterInstant275051000000JPY
Liabilities and equity IFRSPrior1YearInstant345981000000JPY
Liabilities and equity IFRSCurrentQuarterInstant357463000000JPY
Revenue IFRSPrior1YTDDuration46403000000JPY
Revenue IFRSCurrentYTDDuration56996000000JPY
Cost of sales IFRSPrior1YTDDuration18106000000JPY
Cost of sales IFRSCurrentYTDDuration23670000000JPY
Gross profit IFRSPrior1YTDDuration28297000000JPY
Gross profit IFRSCurrentYTDDuration33326000000JPY
Selling general and administrative expenses IFRSPrior1YTDDuration13059000000JPY
Selling general and administrative expenses IFRSCurrentYTDDuration15001000000JPY
Share of profit loss of investments accounted for using equity method IFRSPrior1YTDDuration-192000000JPY
Share of profit loss of investments accounted for using equity method IFRSCurrentYTDDuration190000000JPY
Gain relating to loss of control over subsidiaries IFRSPrior1YTDDuration9443000000JPY
Gain relating to loss of control over subsidiaries IFRSCurrentYTDDuration－JPY
Other income IFRSPrior1YTDDuration309000000JPY
Other income IFRSCurrentYTDDuration338000000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 12 of 12 passed
balance sheet identityconsolidated 2022-03-31pass
balance sheet identityconsolidated 2022-06-30pass
dei present pass
period resolution pass
statement vs summary · net income attributable to parentconsolidated 2021-04-01/2021-06-30pass
statement vs summary · net income attributable to parentconsolidated 2022-04-01/2022-06-30pass
statement vs summary · operating cash flowconsolidated 2021-04-01/2021-06-30pass
statement vs summary · operating cash flowconsolidated 2022-04-01/2022-06-30pass
statement vs summary · revenueconsolidated 2021-04-01/2021-06-30pass
statement vs summary · revenueconsolidated 2022-04-01/2022-06-30pass
statement vs summary · total assetsconsolidated 2022-03-31pass
statement vs summary · total assetsconsolidated 2022-06-30pass